All In Biotech

Drug Trial Radar · NCT06971900

GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

A Phase 2a, Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults With Erythropoietic Protoporphyria

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Apr 4, 2025

Primary completion

Nov 22, 2025

Study completion Nov 24, 2025

Sponsor

Lead sponsor
Portal Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Celerion
First posted
May 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2a study of PORT-77 in adults with erythropoietic protoporphyria (EPP)

Conditions

  • Erythropoietic Protoporphyria (EPP)

Interventions

  • PORT-77Drug

    Active oral dose form

  • PlaceboDrug

    Matching inactive oral dose form

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma PPIX levelTime frame: 9 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.